Details for Patent: 10,940,278

Which drugs does patent 10,940,278 protect, and when does it expire?

Patent 10,940,278 protects TRUDHESA and is included in one NDA.

This patent has seventeen patent family members in eight countries.

Summary for Patent: 10,940,278

Patent landscape, scope, and claims:

Title:	Nozzles for nasal drug delivery
Abstract:	A nozzle for use in delivering a mixture of aerosol propellant and drug formulation. The nozzle includes a drug product inlet configured to receive a mixture of aerosolized propellant and an intranasal dosage form. The inlet is disposed at the proximal end. A nozzle body is secured to the drug product inlet. Two or more channels are disposed within the body. Two or more orifice apertures are disposed at the distal end of the nozzle.
Inventor(s):	Hoekman; John D. (Seattle, WA), Hite; Michael (Normandy Park, WA), Brunelle; Alan (Woodinville, WA), Relethford; Joel (Everett, WA)
Assignee:	IMPEL NEUROPHARMA, INC. (Seattle, CA)
Application Number:	15/890,266
Patent Claim Types: see list of patent claims	Delivery; Device; Dosage form;

Drugs Protected by US Patent 10,940,278

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Impel Pharms	TRUDHESA	dihydroergotamine mesylate	SPRAY, METERED;NASAL	213436-001	Sep 2, 2021		RX	Yes	Yes	10,940,278		Y

International Family Members for US Patent 10,940,278

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2012253569
Australia	2018200530
Brazil	112013028572
Canada	2835208
China	103619485